Revolution Medicines (RVMD) Income from Continuing Operations (2019 - 2026)
Revolution Medicines' (RVMD) quarterly Income from Continuing Operations came in at 453816000.0 in Q1 2026, down 112.64% year-on-year from 3589223075.01 in Q1 2025, and down 159.21% quarter-over-quarter from 766409000.0 in Q4 2025.
Revolution Medicines (RVMD) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Revolution Medicines' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 453816000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 112.64% year-over-year to 453816000.0 in Q1 2026; TTM through Mar 2026 was 240400000.0, a 65.53% increase from a year earlier, with the FY2024 full-year figure at 600046000.0, down 36.31% from the prior year.
- Income from Continuing Operations retreated to 453816000.0 in Q1 2026 per RVMD's latest filing, from 766409000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 766409000.0 in Q4 2025 and bottomed at 453816000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 116003000.0 (2024), against an average of 102517764.71.
- Across the five-year window, Income from Continuing Operations plunged 192.58% in 2023 and jumped 494.0% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 56527000.0 in 2022, then tumbled by 192.58% to 165385000.0 in 2023, then decreased by 17.62% to 194522000.0 in 2024, then soared by 494.0% to 766409000.0 in 2025, then sank by 159.21% to 453816000.0 in 2026.
- Per Business Quant, the three latest RVMD Income from Continuing Operations figures stand at 453816000.0 (Q1 2026), 766409000.0 (Q4 2025), and 305206000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -453.82 Mn |
| Dec 31, 2025 | 766.41 Mn |
| Sep 30, 2025 | -305.21 Mn |
| Jun 30, 2025 | -247.79 Mn |
| Mar 31, 2025 | -213.42 Mn |
| Dec 31, 2024 | -194.52 Mn |
| Sep 30, 2024 | -156.29 Mn |
| Jun 30, 2024 | -133.23 Mn |
| Mar 31, 2024 | -116.00 Mn |
| Dec 31, 2023 | -165.39 Mn |
| Sep 30, 2023 | -108.43 Mn |
| Jun 30, 2023 | -98.30 Mn |
| Mar 31, 2023 | -68.10 Mn |
| Dec 31, 2022 | -56.53 Mn |
| Sep 30, 2022 | -73.33 Mn |
| Jun 30, 2022 | -61.22 Mn |
| Mar 31, 2022 | -57.65 Mn |
| Dec 31, 2021 | -52.68 Mn |
| Sep 30, 2021 | -52.94 Mn |
| Jun 30, 2021 | -44.30 Mn |